Posters

      Association of urinary 11-dehydro-thromboxane B2 levels in smoking, smoking cessation and Tobacco Heating System use

      Gonzalez Zuloeta, A.; Pouly, S.; de La Bourdonnaye, G.; Baker, G.; Luedicke, F.

      Conference date
      Jun 27, 2014
      Conference name
      Society for Epidemiologic Research (SER) 2014
      Link to more information
      Link to more information
      Topic
      Summary

      Smoking has been associated with cardiovascular disease and there is evidence that this might be mediated by the increased production of thromboxane. Whether metabolites of thromboxane, such as 11-dehydro-thromboxane B2 (TXB2), could be used as a biomarker of risk in the assessment of candidate modified risk tobacco products (MRTPS) is not clear. The aim of this literature review and meta-analysis (MA) was to determine the association of smoking status and TXB2 levels. Additionally we evaluated the effect of smoking cessation and the use of a tobacco heated system (THS) currently in development, to urinary levels of 11-dehydro-thromboxane B2. 

      Related Publications

      Nicotine Pharmacokinetics of THS Single Use of a Regular or a Menthol Stick Compared to CIG

      Clinical

      Reduction in exposure to selected harmful and potentially harmful constituents approaching those observed upon smoking abstinence in smokers switching to the menthol Tobacco Heating System 2.2 for three months (Part 1)

      Clinical

      Reduction in exposure to selected harmful and potentially harmful constituents approaching those observed upon smoking abstinence in smokers switching to the menthol Tobacco Heating System 2.2 for three months (Part 1)

      Clinical

      Meta-analysis of the effects of smoking and smoking cessation on triglyceride levels

      Clinical

      Smoking and apolipoprotein levels: A meta-analysis of published data

      Clinical

      Effect of switching from cigarette smoking to the use of the tobacco heating system on periodontitis treatment outcome: Periodontal parameter results from a multicenter Japanese study

      Clinical

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts to develop and assess products that have the potential to reduce individual risk and population harm associated with tobacco use. This site is for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not for advertising or marketing. It is not intended for use by consumers.

      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. Our RRPs are smoke-free products that produce an aerosol that contains far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.